文献速递生殖医学

预测卵巢低反应者IVF中增加与标准促性腺激素剂量的开放标签随机对照试验

Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial.
PubMed 文献 · Hum Reprod · 2022-01-01

该平行开放标签随机对照试验于2019年3月至2021年10月在辅助生殖中心纳入661例年龄<43岁、窦卵泡计数<10的首次IVF女性,比较增加FSH剂量与标准150 IU/天起始的累积活产率。增加组累积活产162/328(49.4%),标准组141/333(42.3%),RR 1.17(95%CI 0.99-1.38),P=0.070,差异未达统计学显著。作者建议此类女性IVF起始采用标准150 IU/天以减少潜在不良反应和费用。

要点

  • 预测卵巢低反应女性增加FSH剂量未显著提高累积活产率(RR 1.17,95%CI 0.99-1.38,P=0.070)。
  • 首次胚胎移植后活产率增加组38.1% vs 标准组35.1%,无显著差异。
  • 作者建议此类女性IVF起始采用标准150 IU/天以减少潜在不良反应和费用。

核心结论

  • 在预测卵巢低反应女性中,未发现增加FSH剂量改善活产率的证据;作者建议IVF起始采用标准150 IU/天以减少潜在不良反应和费用。

研究设计与样本

  • 平行、开放标签随机对照试验,2019年3月至2021年10月在辅助生殖中心进行,纳入年龄<43岁、窦卵泡计数<10的首次IVF女性661例,按意向性分析评估。

主要发现

  • 累积活产:增加组162/328(49.4%)vs 标准组141/333(42.3%),RR 1.17(95%CI 0.99-1.38),风险差0.07(95%CI -0.005-0.15),P=0.070。
  • 首次胚胎移植后活产:增加组125/328(38.1%)vs 标准组117/333(35.1%),RR 1.08(95%CI 0.83-1.33),P=0.428。
  • 累积临床妊娠率:增加组59.1% vs 标准组57.1%,RR 1.04(95%CI 0.91-1.18),P=0.586。
  • 流产率:增加组9.8% vs 标准组14.4%,RR 0.68(95%CI 0.44-1.03),P=0.069。
  • 生化妊娠、持续妊娠、多胎妊娠和异位妊娠等次要结局在首次及累积胚胎移植中两组均无显著差异。

关键数值与推荐

  • 增加剂量组:窦卵泡计数1-6者起始300 IU/天,窦卵泡计数7-9者起始225 IU/天;标准组起始150 IU/天。
  • 主要结局为归因于首次IVF周期的累积活产,包括随机化后18个月内的新鲜及后续冻融周期。
  • 活产定义:妊娠≥24周分娩一个或多个活婴。
  • 试验把握度设定为检测归因于首次IVF周期的活产率11%的差异。

临床怎么用

  • 作者建议预测卵巢低反应女性在IVF起始时采用标准150 IU/天剂量,以减少潜在不良反应和费用。

局限性

  • 研究为开放标签设计,潜在的选择性取消和小剂量调整可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does an increased dosing of FSH improve the live birth rate as compared to standard FSH dosing in expected poor responders who undergo IVF? SUMMARY ANSWER: In this trial, women with an expected poor response allocated to increased FSH dosing did not have a statistically significant increase in cumulative live births as compared to a standard FSH dose. WHAT IS KNOWN ALREADY: Poor ovarian reserve leads to worse IVF outcomes owing to the low number and quality of oocytes. Clinicians often individualize the FSH dose using ovarian reserve tests, including antral follicle count (AFC), and basal plasma FSH or anti-Müllerian hormone level. However, the evidence that increased FSH dosing improves fertility outcomes in women with an expected poor response is lacking. STUDY DESIGN, SIZE, DURATION: We performed a parallel, open-label randomized controlled trial between March 2019 and October 2021 in an assisted reproduction centre. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women <43 years of age with AFC <10 referred for their first IVF cycle were randomized for increased or standard FSH dosing. In participants allocated to increased FSH dosing, women with AFC 1-6 started with 300 IU/day, while women with AFC 7-9 started with 225 IU/day. In participants allocated to the standard care, women started with 150 IU/day. The primary outcome was cumulative live birth attributable to the first IVF cycle including fresh and subsequent frozen-thawed cycles within 18 months of randomization. Live birth was defined as the delivery of one or more living infants ≥24 weeks' gestation. This trial was powered to detect an 11% difference in live birth attributable to the first IVF cycle. Outcomes were evaluated from an intention-to-treat perspective. MAIN RESULTS AND THE ROLE OF CHANCE: We randomized 661 women to start FSH at increased dosing (n = 328) or standard dosing (n = 333). The primary outcome cumulative live birth occurred in 162/328 (49.4%) women in the increased group versus 141/333 (42.3%) women in the standard group [risk ratio (RR) 1.17 (95% CI, 0.99-1.38), risk difference 0.07 (95% CI, -0.005, 0.15), P = 0.070]. The live birth rate after the first embryo transfer in the increased versus standard group was 125/328 (38.1%) versus 117/333 (35.1%), respectively [RR 1.08 (95% CI, 0.83-1.33), P = 0.428]. Cumulative clinical pregnancy rates were 59.1% versus 57.1% [RR 1.04 (95% CI, 0.91-1.18), P = 0.586] with miscarriage rates of 9.8% versus 14.4% [RR 0.68 (95% CI, 0.44-1.03), P = 0.069] in the increased versus standard group, respectively. Other secondary outcomes, including biochemical pregnancy, ongoing pregnancy, multiple pregnancy and ectopic pregnancy, were not significantly different between the two groups both from the first and cumulative embryo transfer. LIMITATIONS, REASONS FOR CAUTION: As this study is open-label, potential selective cancelling and small dose adjustments could have influenced the results. WIDER IMPLICATIONS OF THE FINDINGS: In women with predicted poor response, we did not find evidence that increased FSH dosing improves live birth rates. A standard dose of 150 IU/day is recommended at the start of IVF in these women to reduce potential adverse effects and costs. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the General Projects of Social Development in Shaanxi Province (No. 2022SF-565). B.W.M. is supported by NHMRC (GNT1176437). B.W.M. reports personal fees from ObsEva, and funding from Merck and Ferring outside the submitted work. TRIAL REGISTRATION NUMBER: Registered at Chinese clinical trial registry (www.chictr.org.cn). Registration number ChiCTR1900021944. TRIAL REGISTRATION DATE: 17 March 2019. DATE OF FIRST PATIENT’S ENROLMENT: 20 March 2019.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Liu X, Wen W, Wang T, et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Hum Reprod. 2022. PMID: 35595197. doi:10.1093/humrep/deac113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。